Physician profile
Stuart Bergman-Bock
NPI 1639463185
$1,156.50
in general payments reported to CMS, 2019-2025
32 companies · $246 in 2025
The $246 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.75 · 2020: $130 · 2021: $87.81 · 2022: $220 · 2023: $272 · 2024: $155 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87.54 | 2020-2025 | Botox |
| Ucb, INC. | $76.89 | 2023-2025 | Briviact, Fintepla |
| Novartis Pharmaceuticals Corporation | $73.80 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $71.11 | 2020-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $59.08 | 2024-2025 | Symbravo, Sunosi |
| Amneal Pharmaceuticals LLC | $58.20 | 2020-2025 | Rytary, Crexont |
| Biogen, INC. | $53.75 | 2021-2025 | Vumerity, Skyclarys, Tysabri |
| Eisai INC. | $53.22 | 2019-2025 | |
| Celgene Corporation | $50.05 | 2022-2023 | Zeposia |
| Csl Behring | $46.74 | 2020-2024 | Hizentra |
| Emd Serono, INC. | $39.37 | 2022-2024 | |
| Kyowa Kirin, INC. | $39.17 | 2020-2023 | Nourianz |
| Boston Scientific Corporation | $37.58 | 2022 | |
| Neurelis, INC. | $32.96 | 2021-2023 | Valtoco |
| Pfizer INC. | $31.25 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $30.76 | 2022-2023 | |
| Argenx US, INC. | $30.51 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $29.04 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $27.02 | 2021-2022 | |
| Amgen INC. | $26.15 | 2020-2022 | |
| Harmony Biosciences LLC | $25.02 | 2024 | |
| Alnylam Pharmaceuticals INC. | $21.11 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.61 | 2025 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $18.85 | 2024 | Lumryz |
| Corium, LLC | $17.43 | 2023 | Adlarity |
| Grifols USA, LLC | $16.44 | 2019 | |
| Allergan, INC. | $16.08 | 2021 | |
| Ge Healthcare | $15.93 | 2020 | |
| Mdd US Operations, LLC | $15.26 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.14 | 2023 | Nuedexta |
| Adamas Pharmaceuticals, INC. | $11.82 | 2021 | |
| Lilly USA, LLC | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Bergman-Bock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.